Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors

Oh, Deok Ja; Park, Yoon Mee; Seo, Young Ik; Lee, Jae Sook; Lee, Ja Young

doi:10.3343/alm.2012.32.3.210

Cited by 31 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Genotype 3a was the predominant genotype in this study, which is in line with the findings of studies conducted in India, Pakistan and Nepal (13,14). However, these findings are inconsistent with the results of studies in Saudi Arabia (15), Kuwait (16), France (17), North American countries (18) and South Korea (19). This difference could be due to high prevalence of intravenous drug abuse in the present study (48.33%) because numerous molecular epidemiological studies suggest an association between genotype 3a transmission and history of intravenous drug abuse (13,16,20).…”

Section: Discussioncontrasting

confidence: 42%

Epidemiologic Study of Hepatitis C Virus Transmission in Lorestan Province (2011-14)

Nazer¹,

Obeidavi²,

Beiranvand

et al. 2016

mljgoums

View full text Add to dashboard Cite

Background and Objective: This study was conducted to evaluate epidemiology of risk factors for hepatitis C virus (HCV) transmission, and determine the association of its genotypes with viral load and response to treatment in patients referred to the Infectious Disease Clinic of Khorramabad.Methods: The study included patients infected with hepatitis C referred to the Infectious Disease Clinic of Khorramabad during 2011-14. Those who met the inclusion criteria were referred to counseling centers for risky behaviors. After collecting demographic and epidemiologic data on the modes of transmission, blood samples were collected for more accurate testing. The erum of patients with hepatitis C was evaluated in terms of HCV genotype and viral load using PCR.Results: Among 120 patients studied, 102 (85%) were male and 18 (15%) were female. The most prevalent genotypes were 3a (63.8%), 1a (25%), 1a/1b (5.2%) and 2 (1.7%). Intravenous drug abuse was the main route of transmission of hepatitis C in the study. The genotypes 3a and 1a had a clear correlation with intravenous drug abuse and history of blood transfusion (P<0.05). It was also found that the patients with genotype 3a show a better initial response to treatment with interferon.Conclusion: The study shows that intravenous drug abuse is the main route of transmission, which highlights the need for intervention and education in this group of patients to prevent disease transmission.

show abstract

Section: Discussioncontrasting

confidence: 42%

Epidemiologic Study of Hepatitis C Virus Transmission in Lorestan Province (2011-14)

Nazer¹,

Obeidavi²,

Beiranvand

et al. 2016

mljgoums

View full text Add to dashboard Cite

show abstract

“…In addition, several previous small-scale studies reported that genotypes 1b (about 50%) and 2a/c (about 50%) were dominant in Korea 6,8. A recent study of the HCV genotypes in Korean blood donors found genotypes 1b, 1a , 2a/c, 2b, 3a, and 4 in 47.7, 1.3, 35.0, 2.3, 1.6, and 0.1%, respectively, but none with genotype 6 9. In comparison, in this study, 1% of the chronic liver disease patients were infected with genotype 6 HCV, confirming the rarity of this genotype in Korea.…”

Section: Discussionmentioning

confidence: 97%

Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6

et al. 2013

View full text Add to dashboard Cite

Background/AimsThe distribution of hepatitis C virus (HCV) genotypes varies geographically. In Korea, genotypes 1 and 2 comprise more than 90% of HCV infections, while genotype 6 is very rare. This study compared the clinical and epidemiological characteristics of patients with genotype 6 HCV infection with those infected with HCV genotypes 1 and 2.MethodsThis was a prospective, multicenter HCV cohort study that enrolled 1,173 adult patients, of which 930 underwent HCV genotype analysis, and only 9 (1.0%) were found to be infected with genotype 6 HCV. The clinical and epidemiological parameters of the genotypes were compared.ResultsThe patients with genotype 6 HCV had a mean age of 41.5 years, 77.8% were male, and they had no distinct laboratory features. A sustained virologic response (SVR) was observed in four (67%) of six patients who received antiviral therapy. Risk factors such as the presence of a tattoo (n=6, 66.7%), more than three sexual partners (n=3, 33.3%), and injection drug use (n=3, 33.3%) were more common among genotype 6 patients than among genotypes 1 or 2.ConclusionsThe epidemiology and treatment response of patients infected with genotype 6 HCV differed significantly from those with genotypes 1 or 2, warranting continuous monitoring.

show abstract

“…The highest seroprevalence of HCV is in those aged ≥70 years; the burden of disease in the elderly Korean population is comparable to the global seroprevalence of HCV (2.31% and 2.35%, respectively) . Genotype 2 has a seroprevalence of 38–46% in Korea . Combination therapy with once‐weekly subcutaneous pegylated interferon‐alpha plus daily oral ribavirin administered for 24 weeks is the standard‐of‐care regimen for the first‐line treatment of Korean patients with chronic genotype 2 HCV infection .…”

Section: Introductionmentioning

confidence: 99%

A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virus

Ahn

Lim

Lee

et al. 2016

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Summary In Korea, patients with chronic hepatitis C virus (HCV) infection are typically treated with pegylated interferon‐alpha plus ribavirin, but interferons are contraindicated in many patients and are often poorly tolerated, particularly by the elderly and those with advanced liver disease. No interferon‐free treatment regimens are approved in Korea. Sofosbuvir is an oral nucleotide analog inhibitor of the HCV nonstructural 5B RNA polymerase. It is approved in the USA, European Union and Japan for treating a number of HCV genotypes, including genotype 2. Genotype 2 has a seroprevalence of 38–46% in Korea. This single‐arm, phase 3b study (NCT02021643) examined the efficacy and safety of sofosbuvir plus ribavirin (12‐week duration) in chronic genotype 2 HCV‐infected treatment‐naive and treatment‐experienced Korean patients with and without cirrhosis. The proportion of patients with sustained virologic response 12 weeks after treatment discontinuation (SVR12) was 97% (125/129), with 96% (101/105) of treatment‐naive and 100% (24/24) of treatment‐experienced patients achieving SVR12. Two patients experienced virologic failure (n = 1, on‐treatment failure; n = 1, relapse). No patient discontinued study treatment due to an adverse event (AE). The most common treatment‐emergent AEs were headache (18%, 23/129) and pruritus (15%, 19/129). Few patients had grade 3 AEs (5%, 6/129) or grade 3 laboratory abnormalities (12%, 15/129). No grade 4 AE was reported. These data suggest that 12 weeks of treatment with the all‐oral, interferon‐free regimen of sofosbuvir plus ribavirin is effective and well tolerated in Korean patients with chronic genotype 2 HCV infection.

show abstract

Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors

Cited by 31 publications

References 21 publications

Epidemiologic Study of Hepatitis C Virus Transmission in Lorestan Province (2011-14)

Epidemiologic Study of Hepatitis C Virus Transmission in Lorestan Province (2011-14)

Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6

A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virus

Contact Info

Product

Resources

About